Article Navigation
Article Contents
-
Introduction
-
Technical approach
-
Results
-
Funding
-
Data availability
-
References
- < Previous
- Next >
Journal Article
, Corentin Chaumont Department of Cardiology, Rouen University Hospital , 1 Rue de Germont, 76031 Rouen , France UNIROUEN, INSERM U1096 , 22 Boulevard Gambetta, 76183 Rouen , France Search for other works by this author on: Oxford Academic Pierre Ollitrault Department of Cardiology, Caen University Hospital , Caen , France Search for other works by this author on: Oxford Academic Arnaud Savoure Department of Cardiology, Rouen University Hospital , 1 Rue de Germont, 76031 Rouen , France Search for other works by this author on: Oxford Academic Raphael Al Hamoud Department of Cardiology, Rouen University Hospital , 1 Rue de Germont, 76031 Rouen , France Search for other works by this author on: Oxford Academic Jonaz Font Department of Cardiology, Caen University Hospital , Caen , France Search for other works by this author on: Oxford Academic Helene Eltchaninoff Department of Cardiology, Rouen University Hospital , 1 Rue de Germont, 76031 Rouen , France UNIROUEN, INSERM U1096 , 22 Boulevard Gambetta, 76183 Rouen , France Search for other works by this author on: Oxford Academic Paul Milliez Department of Cardiology, Caen University Hospital , Caen , France Search for other works by this author on: Oxford Academic Laure Champ-Rigot Department of Cardiology, Caen University Hospital , Caen , France Search for other works by this author on: Oxford Academic Frederic Anselme Department of Cardiology, Rouen University Hospital , 1 Rue de Germont, 76031 Rouen , France UNIROUEN, INSERM U1096 , 22 Boulevard Gambetta, 76183 Rouen , France Corresponding author. Tel: +33 2 32 88 81 11; fax: +33 2 32 88 81 23. E-mail address: Frederic.anselme@chu-rouen.fr Search for other works by this author on: Oxford Academic
Corentin Chaumont and Pierre Ollitrault contributed equally to the study.
Conflict of interest: A.S., R.A.H., J.F., H.E., and P.M.: none declared; C.C. is a consultant for and has received lecture fees from Medtronic. P.O. has received consulting fees from Biotronik, Boston Scientific, Biosense Webster, Medtronic, and Zoll. L.C.-R. has received consulting fees from Boston Scientific, Medtronic, and MicroPort CRM. F.A. a is consultant for and has received lecture fees from Boston Scientific, Medtronic, and MicroPort CRM.
Author Notes
EP Europace, Volume 26, Issue 10, October 2024, euae262, https://doi.org/10.1093/europace/euae262
Published:
22 October 2024
Article history
Received:
12 September 2024
Accepted:
01 October 2024
Corrected and typeset:
22 October 2024
Published:
22 October 2024
- Split View
- Views
- Article contents
- Figures & tables
- Video
- Audio
- Supplementary Data
-
Cite
Cite
Corentin Chaumont, Pierre Ollitrault, Arnaud Savoure, Raphael Al Hamoud, Jonaz Font, Helene Eltchaninoff, Paul Milliez, Laure Champ-Rigot, Frederic Anselme, Cavotricuspid isthmus ablation using a pentaspline pulsed field ablation catheter: feasibility and acute results, EP Europace, Volume 26, Issue 10, October 2024, euae262, https://doi.org/10.1093/europace/euae262
Close
Search
Close
Search
Advanced Search
Search Menu
Pulsed field ablation, Atrial flutter, Cavotricuspid isthmus, Atrial fibrillation
Introduction
The efficacy and safety of pulmonary vein isolation (PVI) using pulsed field ablation (PFA) have been largely demonstrated.1–3 During atrial fibrillation (AF) catheter ablation, additional cavotricuspid isthmus (CTI) ablation is often required.4 In patients undergoing PVI using the pentaspline PFA catheter (Boston Scientific Inc., Menlo Park, USA), it remains unclear whether CTI ablation can be achieved using the same catheter. To address this question, we prospectively included all consecutive patients undergoing combined PVI and CTI ablation with the pentaspline PFA catheter in two academic hospitals from June 2023 to March 2024. All patients provided informed consent, and the study was approved by the local institutional review board.
Technical approach
All procedures were performed under general anaesthesia with uninterrupted oral anticoagulation. Pulmonary vein isolation was performed as previously described.5 The pentaspline catheter was then positioned in the right atrium, and a quadripolar catheter was positioned in the coronary sinus (CS). Cavotricuspid isthmus ablation was performed during CS ostium pacing for patients in sinus rhythm or during typical atrial flutter confirmed by entrainment manoeuvres. Based on anatomy and operators’ preference, the pentaspline catheter was positioned on the CTI using a direct approach in deployed configuration (direct ‘flower’) or indirect approach with a lateral loop in the right atrium and a semi-deployed configuration (indirect ‘basket’) (Figure 1A).
Figure 1
(A) Pentaspline PFA catheter positioning during CTI ablation. (B) Sinus rhythm restoration observed after the first PFA application. Note the widely separated (105 ms) local double potentials alongside the ablation line during proximal CS pacing (stars and lines). (C) 3D electroanatomical map of the right atrium pre- and post-CTI ablation using the pentaspline PFA catheter in indirect ‘basket’ configuration. Activation maps pre- and post-ablation (top panels). Early activation is displayed as red and late activation as purple. Note the propagation block on the CTI and the late activation on the lateral side of the ablation line during proximal CS pacing. Voltage maps pre- and post-ablation (bottom panels). Normal bipolar voltage is displayed as purple. Low voltage areas are displayed across the rest of the color scale. Note the extensive low voltage (<0.05 mV) on the CTI with normal voltage (>0.5 mV) in the lateral and septal regions of the CTI. AFl, atrial flutter; CTI, cavotricuspid isthmus; IVC, inferior vena cava; PFA, pulsed field ablation; PVI, pulmonary vein isolation; TA, tricuspid annulus.
Open in new tabDownload slide
Stable positioning at the medial CTI was validated anatomically in left anterior oblique 45° and right anterior 30° oblique views, aiming to obtain right atrial near-field electrograms and right ventricular far-field electrograms on the pentaspline catheter. A bolus of nitroglycerin (2 mg) was administered via the femoral venous sheath 1–5 min prior to the first PFA application. A minimum of four PFA applications were delivered, with at least two additional applications after achieving CTI block. The total number of applications was at the operators’ discretion. Twelve-lead ECG was monitored continuously, focusing on ST-segment changes. Complete bidirectional CTI block was defined according to the differential pacing technique previously described.6 The presence of widely spaced (>100 ms) double atrial potentials along the ablation line was also assessed.7
Results
This cohort included 32 consecutive patients (Table 1). Cavotricuspid isthmus ablation was performed with the pentaspline PFA catheter in a direct ‘flower’ configuration for 21 patients (66%) and indirect ‘basket’ configuration for 9 patients (28%). Both configurations were used in two patients (6%). Sinus rhythm restoration was observed after the first PFA application in 17/19 patients (89%) with ongoing typical atrial flutter (Figure 1B). The median number of PFA applications was 6, interquartile range (IQR) 5–8 in ‘flower’ configuration, and 6, IQR 6–10 in ‘basket’ configuration. Acute bidirectional conduction block within the CTI was obtained in all patients. Widely separated (>100 ms) local double potentials alongside the ablation line could be recorded by the pentaspline catheter in 21 patients (66%) and clearly appeared after the first PFA application in 17/21 patients. Double potentials were visualized in all the nine ‘basket-only’ configuration cases and in 12/23 cases (52%) using ‘flower’ configuration, either ‘flower-only’ or ‘flower-basket’ (P = 0.01) (Figure 1B). The mean duration from insertion of the PFA catheter into the right atrium to completion and assessment of complete CTI block was 8.2 ± 2.6 min. After 20-min waiting period, none of the patients exhibited conduction recovery across the CTI. None of the patients developed atrio-ventricular (AV) conduction disturbance, ST-segment elevation, or haemodynamic instability following the PFA applications. There were no notable clinical haemodynamic consequences after nitroglycerin injection. In the five patients who underwent 3D electroanatomical mapping pre- and post-CTI ablation for illustrative purpose, the voltage maps showed extensive low voltage and propagation block on the CTI, but with normal voltage in the lateral and septal regions of the CTI, notably at the triangle of Koch (Figure 1C). At 6-month follow-up, 30/32 patients (94%) did not experience symptom recurrence and were in sinus rhythm on 12-lead ECG. Two patients experienced left atrial arrhythmia recurrences and underwent redo procedures with 3D electroanatomical mapping, showing persistent bidirectional block along the CTI. There was no acute coronary event during the follow-up period.
Table 1
Open in new tab
Patients baseline characteristics
Baseline characteristics | All patients (n = 32) mean ± SD, median (IQR) or n (%) |
---|---|
Age, years | 62 ± 8 |
Sex (male) | 27 (84) |
AF type | |
Paroxysmal | 13 (41) |
Persistent | 19 (59) |
Indication for CTI ablation | |
Documented typical AFl before the procedure | 13 (41) |
Typical AFl at the beginning of the procedure | 8 (25) |
Typical AFl induced during the procedure | 11 (34) |
Hypertension | 17 (53) |
Diabetes | 5 (16) |
History of stroke or TIA | 2 (6) |
Coronary artery disease (stent or CABG) | 3 (9) |
Heart failure | 13 (41) |
CHA2DS2-VASc | 2 (1–3) |
Body mass index, kg/m2 | 28 ± 4 |
LVEF | |
LVEF > 50% | 20 (63) |
LVEF 40–50% | 4 (13) |
LVEF < 40% | 8 (25) |
Antiarrhythmic medications | |
Class Ic | 9 (28) |
Amiodarone | 13 (41) |
Baseline characteristics | All patients (n = 32) mean ± SD, median (IQR) or n (%) |
---|---|
Age, years | 62 ± 8 |
Sex (male) | 27 (84) |
AF type | |
Paroxysmal | 13 (41) |
Persistent | 19 (59) |
Indication for CTI ablation | |
Documented typical AFl before the procedure | 13 (41) |
Typical AFl at the beginning of the procedure | 8 (25) |
Typical AFl induced during the procedure | 11 (34) |
Hypertension | 17 (53) |
Diabetes | 5 (16) |
History of stroke or TIA | 2 (6) |
Coronary artery disease (stent or CABG) | 3 (9) |
Heart failure | 13 (41) |
CHA2DS2-VASc | 2 (1–3) |
Body mass index, kg/m2 | 28 ± 4 |
LVEF | |
LVEF > 50% | 20 (63) |
LVEF 40–50% | 4 (13) |
LVEF < 40% | 8 (25) |
Antiarrhythmic medications | |
Class Ic | 9 (28) |
Amiodarone | 13 (41) |
AF, atrial fibrillation; AFl, atrial flutter; CABG, coronary artery bypass graft; LVEF, left ventricular ejection fraction; TIA, transient ischaemic attack.
Table 1
Open in new tab
Patients baseline characteristics
Baseline characteristics | All patients (n = 32) mean ± SD, median (IQR) or n (%) |
---|---|
Age, years | 62 ± 8 |
Sex (male) | 27 (84) |
AF type | |
Paroxysmal | 13 (41) |
Persistent | 19 (59) |
Indication for CTI ablation | |
Documented typical AFl before the procedure | 13 (41) |
Typical AFl at the beginning of the procedure | 8 (25) |
Typical AFl induced during the procedure | 11 (34) |
Hypertension | 17 (53) |
Diabetes | 5 (16) |
History of stroke or TIA | 2 (6) |
Coronary artery disease (stent or CABG) | 3 (9) |
Heart failure | 13 (41) |
CHA2DS2-VASc | 2 (1–3) |
Body mass index, kg/m2 | 28 ± 4 |
LVEF | |
LVEF > 50% | 20 (63) |
LVEF 40–50% | 4 (13) |
LVEF < 40% | 8 (25) |
Antiarrhythmic medications | |
Class Ic | 9 (28) |
Amiodarone | 13 (41) |
Baseline characteristics | All patients (n = 32) mean ± SD, median (IQR) or n (%) |
---|---|
Age, years | 62 ± 8 |
Sex (male) | 27 (84) |
AF type | |
Paroxysmal | 13 (41) |
Persistent | 19 (59) |
Indication for CTI ablation | |
Documented typical AFl before the procedure | 13 (41) |
Typical AFl at the beginning of the procedure | 8 (25) |
Typical AFl induced during the procedure | 11 (34) |
Hypertension | 17 (53) |
Diabetes | 5 (16) |
History of stroke or TIA | 2 (6) |
Coronary artery disease (stent or CABG) | 3 (9) |
Heart failure | 13 (41) |
CHA2DS2-VASc | 2 (1–3) |
Body mass index, kg/m2 | 28 ± 4 |
LVEF | |
LVEF > 50% | 20 (63) |
LVEF 40–50% | 4 (13) |
LVEF < 40% | 8 (25) |
Antiarrhythmic medications | |
Class Ic | 9 (28) |
Amiodarone | 13 (41) |
AF, atrial fibrillation; AFl, atrial flutter; CABG, coronary artery bypass graft; LVEF, left ventricular ejection fraction; TIA, transient ischaemic attack.
This is the first real-life case series of consecutive patients undergoing CTI ablation using a pentaspline PFA catheter. This approach was successfully and safely performed in 32 cases. We observed a high acute efficacy with sinus rhythm restoration after the first PFA application in 89% of patients and persistence of a bidirectional CTI block after a 20-min waiting period in all. The direct ‘flower’ or indirect ‘basket’ approaches were similarly efficient with a median number of six applications. The safety profile also appeared satisfactory with no patients developing AV conduction disturbance or ST-segment elevation, under cover of a 2 mg bolus of nitroglycerin. The pentaspline PFA catheter has been developed to perform PVI only but CTI ablation is often required during AF ablation procedure. Using the same catheter to perform both PVI and CTI ablation could be time and cost-saving. Moreover, this could reduce the carbon footprint of the procedure.8 Some concerns have been raised about the risk of coronary spasm associated with the use of the PFA catheter in the CTI. In patients undergoing CTI ablation with a focal PFA catheter, vasospasm of the right coronary artery (RCA) was observed in four of five patients (80%) without nitroglycerin injection.9 Similar results were found with the pentaspline PFA catheter: subtotal vasospasm of the RCA was observed in all patients without nitroglycerin injection whereas only mild to moderate vasospasm occurred in 20% of patients after the administration of intracoronary or intravenous nitroglycerin.10 None of these vasospastic events resulted in ST-segment elevation or arrhythmias.9,10 Contrary to radiofrequency ablation,11,12 it appeared that PFA-induced vasospasm does not lead to any discernible degree of coronary stenosis.13 Intracoronary injection of nitroglycerin appeared unnecessary as an intravenous injection before the first PFA application seemed to be a safe approach.
The optimal number of PFA applications, especially after obtaining CTI block, remains to be determined in order to prevent late reconduction. The safety profile of CTI ablation using the pentaspline PFA catheter observed in our study also has to be further confirmed in larger cohorts.
Funding
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Data availability
The data that support the findings of this study are available on request from the corresponding author, F.A.
References
1
Turagam MK Neuzil P Schmidt B Reichlin T Neven K Metzner A
Safety and effectiveness of pulsed field ablation to treat atrial fibrillation: one-year outcomes from the MANIFEST-PF registry
.
Circulation
2023
;
148
:
35
–
46
.
2
Schmidt B Bordignon S Neven K Reichlin T Blaauw Y Hansen J
EUropean real-world outcomes with Pulsed field ablatiOn in patients with symptomatic atRIAl fibrillation: lessons from the multi-centre EU-PORIA registry
.
Europace
2023
;
25
:
euad185
.
3
Della Rocca DG Marcon L Magnocavallo M Menè R Pannone L Mohanty S
Pulsed electric field, cryoballoon, and radiofrequency for paroxysmal atrial fibrillation ablation: a propensity score-matched comparison
.
Europace
2023
;
26
:
euae016
.
4
Calkins H Hindricks G Cappato R Kim Y-H Saad EB Aguinaga L
2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation
.
Heart Rhythm
2017
;
14
:
e275
–
444
.
5
Chaumont C Hayoun C Savoure A Al Hamoud R Auquier N McDonnell E
Pentaspline pulsed field ablation catheter versus cryoballoon for atrial fibrillation ablation: results from a prospective comparative study
.
J Am Heart Assoc
2024
;
13
:
e033146
.
6
Shah D Haïssaguerre M Takahashi A Jaïs P Hocini M Clémenty J
Differential pacing for distinguishing block from persistent conduction through an ablation line
.
Circulation
2000
;
102
:
1517
–
22
.
7
Anselme F Savouré A Cribier A Saoudi N
Catheter ablation of typical atrial flutter: a randomized comparison of 2 methods for determining complete bidirectional isthmus block
.
Circulation
2001
;
103
:
1434
–
9
.
8
Sacher F Bacquelin R Bessiere F Ditac G Duchateau J Ait-Said M
Position paper on sustainability in cardiac pacing and electrophysiology from the working group of cardiac pacing and electrophysiology of the French Society of Cardiology
.
Arch Cardiovasc Dis
2024
;
117
:
224
–
31
.
9
Malyshev Y Neuzil P Petru J Funasako M Hala P Kopriva K
Nitroglycerin to ameliorate coronary artery spasm during focal pulsed-field ablation for atrial fibrillation
.
JACC Clin Electrophysiol
2024
;
10
:
885
–
96
.
10
Reddy VY Petru J Funasako M Kopriva K Hala P Chovanec M
Coronary arterial spasm during pulsed field ablation to treat atrial fibrillation
.
Circulation
2022
;
146
:
1808
–
19
.
11
Ouali S Anselme F Savouré A Cribier A
Acute coronary occlusion during radiofrequency catheter ablation of typical atrial flutter
.
J Cardiovasc Electrophysiol
2002
;
13
:
1047
–
9
.
12
Bussmann BM De Maria GL Kotronias RA Rajappan K Green PG Pedersen M
Acute right coronary artery occlusion following cavotricuspid isthmus ablation
.
JACC Cardiovasc Interv
2024
;
17
:
97
–
8
.
13
Malyshev Y Neuzil P Petru J Funasako M Hala P Kopriva K
Does acute coronary spasm from pulsed field ablation translate into chronic coronary arterial lesions?
JACC Clin Electrophysiol
2024
;
10
:
970
–
2
.
Author notes
Corentin Chaumont and Pierre Ollitrault contributed equally to the study.
Conflict of interest: A.S., R.A.H., J.F., H.E., and P.M.: none declared; C.C. is a consultant for and has received lecture fees from Medtronic. P.O. has received consulting fees from Biotronik, Boston Scientific, Biosense Webster, Medtronic, and Zoll. L.C.-R. has received consulting fees from Boston Scientific, Medtronic, and MicroPort CRM. F.A. a is consultant for and has received lecture fees from Boston Scientific, Medtronic, and MicroPort CRM.
© The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
Issue Section:
Research letter
Download all slides
Advertisement intended for healthcare professionals
Citations
Views
194
Altmetric
More metrics information
Metrics
Total Views 194
144 Pageviews
50 PDF Downloads
Since 10/1/2024
Month: | Total Views: |
---|---|
October 2024 | 194 |
Citations
Powered by Dimensions
Altmetrics
Email alerts
Article activity alert
Advance article alerts
New issue alert
In progress issue alert
Receive exclusive offers and updates from Oxford Academic
Citing articles via
Google Scholar
-
Latest
-
Most Read
-
Most Cited
More from Oxford Academic
Cardiovascular Medicine
Clinical Medicine
Medicine and Health
Books
Journals
Advertisement intended for healthcare professionals